Tanvex BioPharma Inc
TWSE:6541

Watchlist Manager
Tanvex BioPharma Inc Logo
Tanvex BioPharma Inc
TWSE:6541
Watchlist
Price: 62.1 TWD 0.16% Market Closed
Market Cap: 10.2B TWD
Have any thoughts about
Tanvex BioPharma Inc?
Write Note

P/E
Price to Earnings

-6.3
Current
-4.9
Median
21.6
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-6.3
=
Market Cap
10.2B TWD
/
Net Income
-1.6B TWD
All Countries
Close
Market Cap P/E
KY
Tanvex BioPharma Inc
TWSE:6541
10.2B TWD -6.3
FR
Pharnext SCA
OTC:PNEXF
6T USD -180 834.4
US
Abbvie Inc
NYSE:ABBV
314.6B USD 61.9
US
Amgen Inc
NASDAQ:AMGN
141.2B USD 33.4
US
Gilead Sciences Inc
NASDAQ:GILD
117.3B USD 930.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD -219.6
US
Epizyme Inc
F:EPE
94.1B EUR -472.5
AU
CSL Ltd
ASX:CSL
136.4B AUD 32.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD 16.9
US
Seagen Inc
F:SGT
39.3B EUR -54.7
NL
argenx SE
XBRU:ARGX
36.2B EUR -136.2
Earnings Growth PEG
KY
Tanvex BioPharma Inc
TWSE:6541
Average P/E: 215
Negative Multiple: -6.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 834.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.9
72%
0.9
US
Amgen Inc
NASDAQ:AMGN
33.4
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
930.6
21%
44.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -219.6
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.5 N/A N/A
AU
CSL Ltd
ASX:CSL
32.1
18%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -136.2 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
N/A
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A

See Also

Discover More